LAVAL, QC, May 19 /CNW Telbec/ - Neptune Technologies & Bioressources
Inc. ("Neptune") (NASDAQ.NEPT - TSX.V.NTB) today reports its consolidated
financial results for the fiscal year ended February 28, 2009. Neptune reports
record revenues, EBITDA(1) and first-time profitability for the three-month
period ended February 28, 2009. Neptune and Acasti Pharma amended their stock
Neptune reports consolidated operating results for its nutraceutical
business and for its pharmaceutical subsidiaries Acasti Pharma Inc. and
NeuroBioPharm Inc. Because its fiscal year changed to February 28 from May 31
and in order to make relevant comparisons, the Company compares the results of
the three and nine-month period ended February 28, 2009 to the unaudited three
and nine-month period of the previous fiscal year ended February 29, 2008.
Financial Results: Three-Month Period ended February 28, 2009
- Revenues for the three-month period ended February 28, 2009 totalled a
record $3,772,000, a 31% increase compared to $2,875,000 for the three-
month period ended February 29, 2008.
- EBITDA for the three-month period ended February 28, 2009 reached
$888,000 which represents an increase of 155% compared to $348,000
achieved during the three-month period ended February 29, 2008.
- Net profit for the three-month period ended February 28, 2009 amounted
to $71,000 or $0.002 per share, compared to a net loss of $886,000 or
$0.024 per share, for the three-month period ended February 29, 2008.
Financial Results: Nine-Month Period ended February 28, 2009
- Revenues increased by 20.5% to $8,589,000, during the nine-month period
ended February 28, 2009, from $7,129,000 achieved during the previous
fiscal year nine-month period ended February 29, 2008.
- Consolidated EBITDA for the nine-month period ended February 28, 2009
represents $337,000 compared to $750,000 obtained during the nine-month
period ended February 29, 2008.
- EBITDA for Neptune Nutraceutical, excluding Acasti Pharma et
NeuroBioPharm, for the nine-month period ended February 28, 2009
amounted to $1,238,000 which represents an increase of 65% compared to
the nine-month period ended February 29, 3008.
- Net loss decreased by $1,611,000 and represents $1,889,000 or $0.05 per
share which is an improvement of 46% for the nine-month period ended
February 28, 2009 compared to a net loss of $3,500,000 or $0.095 per
share, for the previous fiscal nine-month period. This improvement is
mainly due to an increase in productivity as well as an increase of
gross margins reflected in the costs of sales and operating expenses.
- The Company believes that Neptune's cash position and financial
performance provide for a self-sustainable profitable nutraceutical
business. As of February 28, 2009, Neptune's cash and cash equivalents
Neptune announces amendments to the Company and the Acasti stock options
Neptune announces that on April 29, 2009, its subsidiary Acasti Pharma
amended the existing stock option plan for directors, officers, employees and
consultants initially adopted on October 8, 2008 (the "Acasti Plan"), as
required by the TSX Venture Exchange. The Acasti Plan now allows the board of
directors of Acasti to grant options for Acasti Class A shares representing up
to 10% of the outstanding issued Acasti shares subject to a maximum of
1,530,000 Acasti options.
On April 29, 2009, Neptune also amended its stock option plan ("Neptune
Plan") to provide that each option granted under the Acasti Plan will reduce
by one the number of shares available for further issuance under the Neptune
Plan and each option cancelled under the Acasti Plan will increase by one, the
number of shares available under the Neptune plan, until the date on which the
shares of Acasti qualify as "exchange-traded securities" under applicable
securities laws and regulations.
The Acasti Plan and annual grant of options to purchase Acasti Class A
shares must be approved each year by disinterested shareholders of Neptune at
its annual general meeting. Accordingly, at the annual general meeting of the
shareholders to be held on June 9, 2009, the disinterested shareholders of
Neptune will be asked to approve the Acasti Plan and the grant of 850,000
stock options to various Acasti directors, officers and employees made on
October 8, 2008.
(1) Earnings before Interest, Taxes, Depreciation, and Amortization
About Neptune Technologies & Bioressources Inc.
Neptune is an industry-recognized leader in the innovation, production
and formulation of science-based and clinically-proven novel phospholipid
products for the nutraceutical and pharmaceutical markets. The Company focuses
on growing consumer health markets including cardiovascular, inflammatory and
neurological disease driven by consumers taking a more proactive approach to
managing health and preventing disease. The Company carries out clinical
trials to show the therapeutic benefits in various medical indications and to
obtain regulatory approved health claims. Neptune is continuously expanding on
its portfolio of intellectual property, clinical studies, regulatory approvals
and health claims. Neptune has its products marketed and distributed in over
20 countries worldwide.
About Acasti Pharma
Acasti Pharma is pursuing pharmaceutical cardiovascular applications with
near-term market opportunities in the medical food and over-the-counter
markets. The development of a prescription drug candidate towards regulatory
approval to conduct clinical trials in the U.S. and Canada is currently in
progress. The business development strategy is to carry out advanced clinical
development and commercialization with multinational pharmaceutical partners.
NeuroBioPharm is pursuing pharmaceutical neurological applications, and a
clinical study for a medical food product with a multinational partner is
already initiated. The development of a prescription drug candidate is
currently in progress. Advanced clinical development and commercialization is
planned to be carried out with multinational partners.
NASDAQ does not accept responsibility for the adequacy or accuracy of
this press release. Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or accuracy of
Statements in this press release that are not statements of historical or
current fact, including statments relating to the Company's expectation
regarding the future performance and marketability of its products, constitute
"forward-looking statements" within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995 and Canadian securities laws. Such
forward-looking statements involve known and unknown risks, uncertainties, and
other unknown factors that could cause the actual results of the Company to be
materially different from historical results or from any future results
expressed or implied by such forward-looking statements. In addition to
statements which explicitly describe such risks and uncertainties, readers are
urged to consider statements labeled with the terms "believes," "belief,"
"expects," "intends," "anticipates,"should," "will" or "plans" to be uncertain
and forward-looking. The forward-looking statements contained herein are also
subject generally to other risks and uncertainties that are described from
time to time in the Company's reports filed with the Securities and Exchange
Commission and the Canadian securities commissions.
For further information:
For further information: Toni Rinow, Ph.D., MBA, Corporate Development &
Investor Relations, Neptune Technologies & Bioressources Inc., (450) 687-2262,
email@example.com; www.neptunebiotech.com; SOURCE: Neptune
Technologies & Bioressources Inc.